NasdaqCM - Delayed Quote USD

Reviva Pharmaceuticals Holdings, Inc. (RVPH)

0.8197
+0.0022
+(0.27%)
At close: May 9 at 4:00:00 PM EDT
0.8035
-0.02
(-1.98%)
After hours: May 9 at 7:00:12 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
0
0
0
0
0
Operating Expense
30,798.8890
30,798.8890
39,503.6360
28,228.7580
10,104.5130
Operating Income
-30,798.8890
-30,798.8890
-39,503.6360
-28,228.7580
-10,104.5130
Net Non Operating Interest Income Expense
342.8720
342.8720
364.6880
182.8020
-2.4140
Other Income Expense
556.7290
556.7290
-104.9400
-194.7090
1,591.0550
Pretax Income
-29,899.2880
-29,899.2880
-39,243.8880
-28,240.6650
-8,515.8720
Tax Provision
19.5140
19.5140
16.9490
20.7770
6.0040
Net Income Common Stockholders
-29,918.8020
-29,918.8020
-39,260.8370
-28,261.4420
-8,521.8760
Diluted NI Available to Com Stockholders
-29,918.8020
-29,918.8020
-39,260.8370
-28,261.4420
-8,521.8760
Basic EPS
-0.90
--
-1.65
-1.25
-0.58
Diluted EPS
-0.90
--
-1.65
-1.25
-0.58
Basic Average Shares
33,147.4240
--
23,798.2030
19,516.4790
14,790.8430
Diluted Average Shares
33,147.4240
--
23,798.2030
19,516.4790
14,790.8430
Total Operating Income as Reported
-30,798.8890
-30,798.8890
-39,503.6360
-28,228.7580
-10,104.5130
Total Expenses
30,798.8890
30,798.8890
39,503.6360
28,228.7580
10,104.5130
Net Income from Continuing & Discontinued Operation
-29,918.8020
-29,918.8020
-39,260.8370
-28,261.4420
-8,521.8760
Normalized Income
-30,485.7416
-30,485.7416
-39,071.8564
-28,107.6219
-9,683.3462
Interest Income
361.3690
361.3690
398.4130
182.8020
--
Interest Expense
18.4970
18.4970
33.7250
--
2.4140
Net Interest Income
342.8720
342.8720
364.6880
182.8020
-2.4140
EBIT
-29,880.7910
-29,880.7910
-39,210.1630
-28,228.7580
-8,513.4580
EBITDA
-29,880.7910
-29,880.7910
-39,210.1630
-28,228.7580
-8,513.4580
Reconciled Depreciation
--
--
--
--
0
Net Income from Continuing Operation Net Minority Interest
-29,918.8020
-29,918.8020
-39,260.8370
-28,261.4420
-8,521.8760
Total Unusual Items Excluding Goodwill
717.6450
717.6450
-239.2160
-194.7090
1,591.0550
Total Unusual Items
717.6450
717.6450
-239.2160
-194.7090
1,591.0550
Normalized EBITDA
-30,598.4360
-30,598.4360
-38,970.9470
-28,034.0490
-10,104.5130
Tax Rate for Calcs
0.0002
0.0002
0.0002
0.0002
0.0003
Tax Effect of Unusual Items
150.7055
150.7055
-50.2354
-40.8889
429.5848
12/31/2021 - 10/18/2018

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ALGS Aligos Therapeutics, Inc.
4.4800
-8.01%
 
CLDI Calidi Biotherapeutics, Inc.
0.4589
+10.58%
 
CRDF Cardiff Oncology, Inc.
2.6600
+1.14%
 
BIVI BioVie Inc.
1.1200
-8.94%
 
IMUX Immunic, Inc.
1.0100
-0.98%
 
SGMT Sagimet Biosciences Inc.
3.2600
+1.87%
 
UNCY Unicycive Therapeutics, Inc.
0.5500
-11.59%
 
NRXP NRx Pharmaceuticals, Inc.
2.0400
-0.49%
 
TERN Terns Pharmaceuticals, Inc.
3.0400
+1.33%
 
EYEN Eyenovia, Inc.
1.0800
-2.70%